Biogen (BIIB) Draws Takeover Interest from Allergan (AGN), Merck (MRK) - DJ

Biogen (BIIB) Sale Dependent on Value of Aducanumab - BMO Capital

BMO Capital analyst M. Ian Somaiya weighed in on Biogen (NASDAQ: BIIB) amid reports Tuesday that the company is in talks with Merck and Allergan on a potential takeout.

Somaiya said a potential sale, in their opinion, is likely dependent on Biogen's... More

Biogen (BIIB) Takeover 'Makes Sense' - Leerink Partners

Leerink Partners analyst Geoffrey Porges weighed in on Biogen (NASDAQ: BIIB) amid reports Tuesday that the company is in talks with Merck and Allergan on a potential takeout.

Porges said while they have no information to confirm the suggestions that Merck (MP) and Allergan (OP) are among the potential suitors, it certainly makes sense to us.

"In our recent notes we have suggested... More

Tecfidera IP the Major Risk of Biogen (BIIB) Takeout - Baird

Baird analyst Brian Skorney weighed in on Biogen (NASDAQ: BIIB) amid reports Tuesday that the company is in talks with Merck and Allergan on a potential takeout.

Skorney commented, "Though we are not surprised that takeout discussions are taking place, we question the... More

Biogen (BIIB) Could Be Worth $375-475/Share in a Takeover - RBC Capital's Yee

Biogen (NASDAQ: BIIB) could be worth $375-$475/share in a takeover RBC Capital's Michael Yee said following reports from the WSJ the company has attracted takeover... More

Standpoint Research Downgrades Biogen (BIIB) to Hold

Standpoint Research downgraded Biogen (NASDAQ: BIIB) from Buy to Hold.

For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.

Shares of Biogen closed at $301.83 yesterday.

Biogen (BIIB) Peers on Watch Amid M&A Chatter (AMGN) (GILD)

Biogen (NASDAQ: BIIB) peers are on watch amid today's M&A chatter. Names include: Celgene (NASDAQ: CELG), Gilead Sciences (NASDAQ: GILD), and Amgen (NASDAQ: AMGN), among others.